The Study
Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging
This study looked at a bunch of people at one point in time and saw that as people get older, certain brain markers tend to change more quickly — like a graph that suddenly gets steeper around age 70. But it didn’t follow people over time, so we can’t say these changes cause dementia — just that they happen together.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists looked at how brain chemicals and memory change as people get older to find when things start speeding up.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 544 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — these ages suggest a critical window in late 50s to early 70s when screening for Alzheimer's might be most useful before symptoms appear.
- 2Memory starts slipping around age 60, amyloid buildup starts at 62, tau proteins spike at 67–73, and brain damage markers rise at 68–71.
- 3But the ratio of bad tau to normal tau doesn't spike.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Alzheimer's & Dementia
Year
2026
Authors
Mingzhao Hu, D. Knopman, Terry M. Therneau, Angela J. Fought, Ekaterina I. Hofrenning, V. Lowe, Ronald C. Petersen, A. Algeciras-Schimnich, C. Jack, Nikki H Stricker, M. Mielke, P. Vemuri, Jon Graff-Radford
Related Content
Claims (6)
Phosphorylated tau protein can be detected in the brain using neuroimaging techniques 12 years before a person shows any signs of Alzheimer's disease.
In people aged around 72.6, levels of a specific form of tau protein in blood called p-tau217 show a distinct change that matches changes in another tau marker, p-tau181, suggesting this protein can reliably detect early tau-related brain changes in late midlife.
In population studies, the ratio of phosphorylated tau to non-phosphorylated tau does not show a clear threshold because rising levels of total tau with age mask the distinct signal of phosphorylated tau.
Between ages 68 and 71, levels of three biological markers in the blood—GFAP, NfL, and p-tau181—rise more rapidly in adults aged 45 to 90, signaling a shift in brain aging processes at the population level.
In adults between 45 and 90 years old, the rate of cognitive decline increases significantly around age 59.8, and this increase happens before similar changes occur in established neurodegenerative biomarkers.
In individuals who develop Alzheimer's disease, abnormal amyloid protein buildup detected by PET scans begins accelerating around age 62.3, and this happens before similar acceleration in tau protein buildup or signs of nerve cell damage.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.